An Open Label Safety Study of COV155 in Subjects With Osteoarthritis or Chronic Low Back Pain

Trial Profile

An Open Label Safety Study of COV155 in Subjects With Osteoarthritis or Chronic Low Back Pain

Completed
Phase of Trial: Phase III

Latest Information Update: 23 Apr 2015

At a glance

  • Drugs Hydrocodone/paracetamol (Primary)
  • Indications Back pain; Osteoarthritis
  • Focus Adverse reactions
  • Sponsors Mallinckrodt Inc.
  • Most Recent Events

    • 03 May 2014 Tolerability results presented at the 33rd Annual Scientific Meeting of the American Pain Society.
    • 13 Jan 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 06 Jun 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top